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OBJECTIVE — To examine the use of mammography and Papanicolaou (Pap) smear among
women with diabetes and to identify predictors of adherence to these tests.
RESEARCH DESIGN AND METHODS — We analyzed data of a nationally represen-
tative sample of Spanish women. Diabetes status was self-reported. Screenings were assessed
askingwhethertheyhadamammography(40years)andaPapsmear(18–69years)withinthe
previous 2 and 3 years, respectively.
RESULTS — Womenwithdiabeteswerelesslikelytoreceivemammography(57.9%)orhave
aPapsmear(61.5%)thanwomenwithoutdiabetes(mammography61.9%,P0.05;Papsmear
65.6%, P  0.05). After adjusting for age, educational level, income, comorbidity, tobacco use,
obesity, and physician visits, the corresponding odds ratios remained signiﬁcant (0.84, 95% CI
0.72–0.97)and(0.82,95%CI0.66–0.98).Highereducationallevelwasapositivepredictorfor
both tests among diabetic women.
CONCLUSIONS — Spanish women with diabetes underuse breast and cervical cancer
screening tests.
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W
omen with diabetes have an in-
creased incidence of breast can-
cer, and women diagnosed with
this cancer who have preexisting diabetes
are at increased risk of breast cancer mor-
talitycomparedwiththosewithoutdiabe-
tes (1,2).
The relationship between diabetes
and risk of cervical cancer remains to be
evaluated, but cervical cancer mortality is
higher in obese women, being these con-
ditionsarestronglyassociatedwithdiabe-
tes (3,4).
Spanish preventive practice guides
recommend mammography for women
aged 50–69 years every 1–2 years and
beginningat40yearsifanyconditionthat
increases risk exists (5). For cervical car-
cinoma, recommendations include
screening with Papanicolaou (Pap) smear
for 2 years starting 3 years after women
become sexually active, and if both yield
normalresults,repeatevery3years(6).In
Spain, population-based programs for
breast and cervical cancer prevention are
established by the Public Health System
and provide free mammography and Pap
smears to target populations (5,6). How-
ever, adherence to the cancer screening
guidelines is not known among Spanish
women with diabetes.
Studies conducted in the U.S. and
Canada have shown that women with di-
abetes undergo mammography and Pap
smear less frequently than women with-
out diabetes (7–10). We aimed to exam-
ine and compare the prevalence of
receiving breast and cervical cancer
screenings among women with and with-
out diabetes and to identify predictors of
adherence to these recommendations
among women with diabetes.
RESEARCH DESIGN AND
METHODS— This study was under-
takenusingindividualizeddataofwomen
includedintheyear2006NationalHealth
Survey (NHS). Details of NHS methodol-
ogy are described elsewhere (11).
Women were classiﬁed as having di-
abetes if they answered afﬁrmatively to
the question: “Has your doctor told you
that you suffer from diabetes?”
Receipt of screening for breast cancer
was assessed by asking women ages 40
yearsandolderwhethertheyhadreceived
a mammography in the previous 2 years
and receipt of screening for cervical can-
cer by asking respondents aged 18–69
years whether they had received a Pap
smear within the previous 3 years. The
independent variables included in our
analyses are shown in Table 1. The vari-
able comorbidity was created and in-
cluded women with one or more of the
following conditions: hypertension, heart
attack, chronic heart disease, asthma, or
chronic bronchitis. The prevalence esti-
mates for receiving cancer screenings by
diabetes status were age-standardized to
the 2006 Spanish population.
We have generated four multivariate
logistic regression models. First, selecting
only women eligible for breast cancer
screening (n  12,429), we used mam-
mography as the dependent variable and
diabetes status (women without diabetes
usedasthereferent)asthemainindepen-
dent variable, adjusting the model by the
rest of covariates. Second, we did the
same for Pap smear. Third, to determine
which variables were independent pre-
dictors of adherence to mammography
among women with diabetes, we selected
women with diabetes eligible for this test
(n  1,222), and using mammography as
the dependent variable, we identiﬁed
whichofthecovariatesanalyzedweresig-
niﬁcantly and independently associated
to mammography uptake. Lastly, we re-
peated this for Pap smear.
RESULTS— Women with diabetes
were signiﬁcantly older than women
withoutdiabetes(meanages67.4vs.50.3
years). The prevalence of comorbidity
(75.2 vs. 38.5%; P  0.05), obesity (56.1
vs.25.3%;P0.05),and“physicianvisit
in the last 4 weeks” (65.7 vs. 44.9%; P 
0.05) was higher among diabetic women,
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23.2%; P  0.05).
Shown in Table 1 are the age-
standardized prevalences of screening
practices broken down by covariates.
Women with diabetes were less likely to
receive mammography (57.9%) or have a
Pap smear (61.5%) than women without
diabetes (mammography 61.9%, P 
0.05; Pap smear 65.6%, P  0.05). After
adjusting for potential confounders, the
corresponding odds ratio remained sig-
niﬁcant (0.84 [95% CI 0.72–0.97] and
0.82 [0.66–0.98]). Shown in Table 1 are
the predictors for receiving the screening
tests analyzed among diabetic women.
Having a mammography within the
last 2 years was associated with age-
groups 50–59 and 60–69 years, higher
educational level, comorbidity, “visiting
any physician in the last 4 weeks,” and
BMI 30 kg/m
2. For Pap smear, the pos-
itive predictors were higher educational
level, higher income, and ex-smoker.
CONCLUSIONS — The main ﬁnd-
ing of this work is that after adjusting by
sociodemographic and health-related
variables, women with diabetes had sig-
niﬁcantly lower use rates of breast- and
cervical cancer–screening tests than
women without diabetes. Previous stud-
ies have shown a reduction in mammog-
raphy and Pap smear among women with
diabetes (7,8,10). Several explications
have been proposed to explain why dia-
betic women are particularly vulnerable
to receiving inadequate preventive care,
including increasing time constraints on
physicians, more complex diabetes man-
agement leaving less time for preventive
management, and a perception of dimin-
ished survival by patients and/or their
physicians possibly making long-term
disease prevention seem less important
(8–10,12).
Our results also agree with other
studiesﬁndingthatlowereconomicaland
educational levels are associated with a
lower compliance with screening recom-
mendations,suggestingthatsociocultural
barrierstoadequatehealtheducationmay
also contribute to lower screening in this
population (5,8–10,13). Finally, as de-
scribed previously, clustering of un-
healthy behavioral risk factors and
nonadherence to cancer screening appear
among Spanish women with diabetes
(9,13,14).
Our study has several limitations.
First, self-reported measures of diabetes
statusandthereceiptofcancerscreenings
were used and are thus subject to recall
bias. Second, the NHS does not collect
information about characteristics of the
diabetes (type, insulin use, duration) that
mayinﬂuencetheadherencetothecancer
screening guidelines. Lastly, the initial
NHSresponseratewas65%,soapossible
nonresponse bias should therefore be
considered (12).
More research is needed to address
theses issues by examining patients, pro-
viders,andorganizationalfactorsthatcan
inﬂuence access to and quality of care of
women with diabetes in Spain. Mean-
while, interventions to increase screening
uptake rates such as letters to patients,
mailed educational materials, electronic
reminder systems, and speciﬁc guidelines
Table 1—Age-standardized prevalences of Spanish women with and without diabetes who had received screenings for breast and cervical
cancers by selected characteristics and predictors of adherence among diabetic women
Mammography (n  12,429) Pap smear (n  13,739)
n
Without
diabetes
With diabetes
(n  1,222)
Without
diabetes
With diabetes
(n  614)
% % Predictors* % % Predictors*
18–29 years old 1,987 NA NA NA 52.0 58.8 1
30–39 years old 3,191 NA NA NA 73.4 75.0 1.8 (0.5–6.5)
40–49 years old 3,414 50.8 46.3 1 75.4 68.6 1.6 (0.5–5.1)
50–59 years old 2,680 88.0 83.3 6.7 (3.6–12.5) 69.4† 57.3 1.0 (0.3–3.2)
60–69 years old 2,467 85.9 84.4 5.9 (3.4–10.4) 45.8† 36.2 0.5 (0.2–1.6)
70 years old 3,868 33.7† 29.2 0.6 (0.3–1.0) NA NA NA
Primary studies or less 2,815 46.2 48.9 1 39.6 29.0 1
Secondary studies 12,332 64.5† 59.4 1.0 (0.7–1.3) 65.1† 62.6 1.8 (1.1–2.8)
University education 2,599 71.5 73.3 2.1 (1.0–5.5) 77.3 78.8 3.7 (1.3–10)
Income/month 1,200 C ¸ 8,156 55.9 55.5 NS 55.5 54.2 1
Income 1,200–100 C ¸ 3,813 66.1† 55.2 NS 68.2† 62.3 1.1 (0.6–1.7)
Income 1,800 C ¸ 3,760 70.1 66.2 NS 76.7 81.6) 2.0 (1.0–4.7)
No comorbidity‡ 10,487 62.3† 56.8 1 66.3† 61.8 NS
Comorbidity 7,346 61.6† 57.3 1.6 (1.1–2.3) 63.8† 57.3 NS
BMI 30 kg/m
2 4,909 56.2† 51.9 1 53.9 58.6 NS
BMI 30 kg/m
2 12,924 64.4 63.9 1.5 (1.2–2.1) 68.4† 62.6 NS
Smokers 3,924 60.03 53.9 NS 67.3† 63.1 1
Ex-smokers 2,398 69.8 62.6 NS 78.3 78.3 2.3 (1.0–4.7)
Nonsmokers 11,511 60.9† 57.9 NS 60.7† 56.2 1.2 (0.7–2.3)
No physician visit§ 8,271 57.6† 54.3 NS 62.9† 60.3 NS
Any physician visit 9,562 66.4† 59.9 1.5 (1.1–2.0) 69.3† 60.8 NS
Total 17,833 61.9† 57.9 NA 65.6† 61.5 NA
The age category prevalences have not been age standardized. *Predictors are shown as adjusted odds ratio with 95% CI, with odds ratio being adjusted for those
covariates with signiﬁcant results. †P  0.05, comparing prevalences between women with and without diabetes. ‡Comorbidity included women with one or more
of the following: hypertension, heart attack, chronic heart disease, asthma, or chronic bronchitis. §Physician visit in the last 4 weeks. NA, not available.
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ered and implemented (7–10,15).
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